Caribou Biosciences Inc (CRBU) Earnings Report, Financial Results, Financial analysis

Caribou Biosciences Inc reported IV. Quarter net loss per share of $-0.36 compare to earnings per share of $0.91 in the same quarter a year ago and improved compare to net loss per share of $-0.44 realized in previous quarter.

*IV. Quarter*
Earnings Per Share	Revenues
$ -0.36	$ 4 Mill
$-1.27	$+9M

Caribou Biosciences Inc 's Revenue rose by -167.71 % in IV. Quarter (Dec 31 2022) year on year, to $4 million and advanced by 11.78 % sequentially.

Caribou Biosciences Inc is Expected to report next financial results on May 08, 2023.

More on CRBU's Income Statement

CRBU's NET INCOME

Caribou Biosciences Inc 's in IV. Quarter recorded net loss of $-26.989 million, compare to net income of $35.285 million achieved in IV. Quarter a year ago.

Sequentially net loss advanced

More on CRBU's Growth

Caribou Biosciences Inc Inventories
In IV. Quarter company's net cash and cash equivalents decreased by $-24 million, capital expenditures fell by 112.70%, to $-1 millions compare to same quarter a year ago and rose by -11.91% from III. Quarter (Sep 30 2022).

More on CRBU's Cash flow Statement

Earnings quality

Caribou Biosciences Inc does not pay out common stock dividend.

In trailing twelve-month period Caribou Biosciences Inc payed $ -1.50 cash per share, on a free-cash flow basis .

Book value fell by -6.77 % sequentially to $4.96 per share, -23.16% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 4.96 per share from $ 5.32.

Company repurchased 0.26 million shares or 0.43 % in IV. Quarter.

• More on CRBU's Dividends

Market Capitalization (Millions)	322
Shares Outstanding (Millions)	61
Total Debt (Millions $)	-
Revenue (TTM) (Millions $)	14
Net Income (TTM) (Millions $)	-99
Cash Flow (TTM) (Millions $)	-182
Capital Exp. (TTM) (Millions $)	-6
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-

Earnings quality

Caribou Biosciences Inc does not pay out common stock dividend.

In trailing twelve-month period Caribou Biosciences Inc had negative $ -1.50 cash flow per share, on a free-cash flow basis .

Book value fell by -6.77 % sequentially to $4.96 per share, -23.16% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 4.96 per share from $ 5.32.

Company repurchased 0.26 million shares or 0.43 % in IV. Quarter.

• More on CRBU's Balance Sheets

Market Capitalization (Millions)	322
Shares Outstanding (Millions)	61
Total Debt (Millions $)	-
Revenue (TTM) (Millions $)	14
Net Income (TTM) (Millions $)	-99
Cash Flow (TTM) (Millions $)	-182
Capital Exp. (TTM) (Millions $)	-6
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-


Economy Advance Monthly Sales Consumer Price Index CPI Producer Price Index PPI Retail Inventories Personal Income Gross Domestic Product GDP Money Supply Industrial Production Productivity Employment Situation US International Trade Factory Orders Durable Goods Construction Spending Housing Starts Vehicle Unit Sales	Stocks Event Calendar TLIS's Profile Stock Price TLIS's Financials Business Description Fundamentals Charts & Quotes TLIS's News Suppliers TLIS's Competitors Customers & Markets Economic Indicators TLIS's Growth Company Segments	Screening Stock Performance Growth Rates Profitability Valuation Dividend Financial Strength Efficiency Largest Companies Management Effectivness

Caribou Biosciences Inc

CRBU's Financial Statements and Analysis